Treatment of non-small cell lung cancer with EGFR-mutations
K Yoneda, N Imanishi, Y Ichiki, F Tanaka - Journal of UOEH, 2019 - jstage.jst.go.jp
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
Treatment of Non-small Cell Lung Cancer with EGFR-mutations
K Yoneda, N Imanishi, Y Ichiki… - Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
Treatment of Non-small Cell Lung Cancer with EGFR-mutations.
K Yoneda, N Imanishi, Y Ichiki, F Tanaka - Journal of UOEH, 2019 - europepmc.org
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
[PDF][PDF] Treatment of Non-small Cell Lung Cancer with EGFR-mutations
K Yoneda, N Imanishi, Y Ichiki, F Tanaka - scholar.archive.org
The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and develop-ment of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …
and develop-ment of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …